MX2017012613A - Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm. - Google Patents

Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.

Info

Publication number
MX2017012613A
MX2017012613A MX2017012613A MX2017012613A MX2017012613A MX 2017012613 A MX2017012613 A MX 2017012613A MX 2017012613 A MX2017012613 A MX 2017012613A MX 2017012613 A MX2017012613 A MX 2017012613A MX 2017012613 A MX2017012613 A MX 2017012613A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
imidazolonyl
quinolines
atm kinase
atm
Prior art date
Application number
MX2017012613A
Other languages
English (en)
Inventor
Fuchss Thomas
Schiemann Kai
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2017012613A publication Critical patent/MX2017012613A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuesto de la fórmula (I), en la cual R1, R3, Het1 y HET tienen los significados dados en la reivindicación 1, son inhibidores de cinasa ATM y se pueden emplear, inter alia, para el tratamiento de cáncer.
MX2017012613A 2015-04-02 2016-03-31 Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm. MX2017012613A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15000968 2015-04-02
PCT/EP2016/000542 WO2016155884A1 (de) 2015-04-02 2016-03-31 Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren

Publications (1)

Publication Number Publication Date
MX2017012613A true MX2017012613A (es) 2018-01-24

Family

ID=52814780

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020011558A MX2020011558A (es) 2015-04-02 2016-03-31 Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
MX2017012613A MX2017012613A (es) 2015-04-02 2016-03-31 Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020011558A MX2020011558A (es) 2015-04-02 2016-03-31 Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.

Country Status (24)

Country Link
US (5) US10457677B2 (es)
EP (3) EP3868761B1 (es)
JP (2) JP6791873B2 (es)
KR (2) KR102652052B1 (es)
CN (3) CN111689963A (es)
AU (3) AU2016239270B2 (es)
BR (1) BR122019005502B1 (es)
CA (1) CA2981365A1 (es)
DK (2) DK3560924T3 (es)
ES (3) ES2946507T3 (es)
HR (2) HRP20191396T1 (es)
HU (2) HUE045477T2 (es)
IL (3) IL254714B (es)
LT (2) LT3560924T (es)
MX (2) MX2020011558A (es)
PL (2) PL3277681T3 (es)
PT (2) PT3560924T (es)
RS (2) RS59139B1 (es)
RU (1) RU2743343C2 (es)
SG (2) SG10202002181UA (es)
SI (2) SI3277681T1 (es)
TR (1) TR201911244T4 (es)
WO (1) WO2016155884A1 (es)
ZA (1) ZA201707423B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016239270B2 (en) * 2015-04-02 2020-03-26 Merck Patent Gmbh Imidazolonyl quinolines and use thereof as ATM kinase inhibitors
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
WO2018153365A1 (zh) * 2017-02-27 2018-08-30 上海瑛派药业有限公司 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
KR20200110377A (ko) 2018-01-12 2020-09-23 프로린크스 엘엘시 조합 용량의 독성을 최소화하기 위한 프로토콜 및 검증을 위한 조영제
RU2020133020A (ru) 2018-03-14 2022-04-14 Мерк Патент Гмбх Соединения и их применения для лечения опухолей у субъекта
CN116925043A (zh) 2018-04-12 2023-10-24 拜耳公司 杂芳基-三唑化合物
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
GB201814487D0 (en) * 2018-09-06 2018-10-24 Cycle Pharmaceuticals Ltd Cancer
CN109045042A (zh) * 2018-09-21 2018-12-21 上海交通大学医学院附属上海儿童医学中心 Atm抑制剂在制备抑制急性淋巴细胞性白血病复发的药物中的应用
WO2020063855A1 (zh) * 2018-09-30 2020-04-02 南京明德新药研发有限公司 喹啉并吡咯烷-2-酮类衍生物及其应用
JP2022526926A (ja) 2019-03-27 2022-05-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング イミダゾロニルキノリン化合物およびそれらの治療への使用
WO2021022078A1 (en) * 2019-07-30 2021-02-04 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
JP2023501971A (ja) 2019-11-01 2023-01-20 アレス トレーディング ソシエテ アノニム 癌の治療のための、放射線療法と共に用いるＰＤ－１、ＴＧＦβ、及びＡＴＭの組み合わせ阻害
EP4069366A1 (en) * 2019-12-04 2022-10-12 CHDI Foundation, Inc. Atm kinase inhibitors and compositions and methods of use thereof
CN115003672A (zh) * 2020-01-09 2022-09-02 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
WO2021197339A1 (zh) * 2020-03-30 2021-10-07 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
CN115916203A (zh) * 2020-06-18 2023-04-04 默克专利股份公司 用于治疗病毒感染的化合物
EP4171651A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and atm inhibitor
JP2023542496A (ja) 2020-09-18 2023-10-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬製剤
WO2022060377A1 (en) * 2020-09-21 2022-03-24 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
DK1879893T3 (da) 2005-03-21 2010-09-13 Ferrer Int Fremgangsmåde til fremstilling af 1-substituerede 1H-imidazo[4,5-c]quinolin-4-aminforbindelser og mellemprodukter dertil
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2129379B1 (en) 2007-02-20 2019-04-10 Novartis AG Imidazoquinolines as dual lipid kinase and mtor inhibitors
EP2474323A3 (en) 2008-03-26 2012-10-10 Novartis AG Imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
DK2299821T3 (en) * 2008-06-10 2016-02-15 Abbvie Inc Tricyclic compounds
EP2617414A3 (en) 2008-10-01 2013-11-06 Novartis AG Smoothened antagonism for the treatment of hedgehog pathway-related disorders
CN102803259A (zh) 2009-06-04 2012-11-28 诺瓦提斯公司 用于治疗增殖性疾病的1H-咪唑并[4,5-c]喹啉酮化合物
MA33332B1 (fr) * 2009-06-04 2012-06-01 Novartis Ag Dérivés de la 1h-imidazo[4,5-c]quinolinone
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
MX2012010557A (es) * 2010-03-16 2012-10-05 Merck Patent Gmbh Morfolinilquinazolinas.
EP2585461B1 (en) * 2010-06-28 2020-02-26 Merck Patent GmbH 2,4-diaryl-substituted [1,8]naphthyridines as kinase inhibitors for use against cancer
CN102372711B (zh) 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CN102399218A (zh) 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
MX2013006187A (es) 2010-12-03 2013-07-15 Novartis Ag Composiciones farmaceuticas.
CN103012398B (zh) 2011-09-19 2015-10-14 上海恒瑞医药有限公司 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
US9879003B2 (en) 2012-04-11 2018-01-30 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
US20150157645A1 (en) 2012-06-06 2015-06-11 Samit Hirawat Combination of a 17-alpha-hydroxylase (c17,20-lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
NO2714752T3 (es) * 2014-05-08 2018-04-21
AU2016239270B2 (en) * 2015-04-02 2020-03-26 Merck Patent Gmbh Imidazolonyl quinolines and use thereof as ATM kinase inhibitors

Also Published As

Publication number Publication date
IL271494A (en) 2020-02-27
ES2741853T3 (es) 2020-02-12
LT3560924T (lt) 2021-08-25
DK3277681T3 (da) 2019-07-29
MX2020011558A (es) 2022-03-09
US20180072715A1 (en) 2018-03-15
RS59139B1 (sr) 2019-09-30
ES2946507T3 (es) 2023-07-20
HUE054745T2 (hu) 2021-09-28
DK3560924T3 (da) 2021-06-28
PT3560924T (pt) 2021-07-02
IL271494B (en) 2021-05-31
AU2016239270B2 (en) 2020-03-26
IL254714B (en) 2020-01-30
KR20240044525A (ko) 2024-04-04
HRP20210981T1 (hr) 2021-09-17
BR122019005502B1 (pt) 2024-02-27
IL282584B (en) 2021-12-01
JP7111790B2 (ja) 2022-08-02
CN107889488A (zh) 2018-04-06
US10745399B2 (en) 2020-08-18
AU2016239270A1 (en) 2017-11-16
AU2020204241B2 (en) 2022-11-17
SG11201708065QA (en) 2017-10-30
RU2017138100A (ru) 2019-05-08
SI3277681T1 (sl) 2019-09-30
PL3560924T3 (pl) 2021-10-11
RU2017138100A3 (es) 2019-10-04
KR102652052B1 (ko) 2024-03-27
JP2021046403A (ja) 2021-03-25
EP3277681A1 (de) 2018-02-07
CN111689963A (zh) 2020-09-22
LT3277681T (lt) 2019-08-12
EP3277681B1 (de) 2019-05-08
CN111747952A (zh) 2020-10-09
EP3560924B1 (de) 2021-03-31
ZA201707423B (en) 2021-05-26
ES2880626T3 (es) 2021-11-25
PT3277681T (pt) 2019-08-20
JP2018510191A (ja) 2018-04-12
KR20170132323A (ko) 2017-12-01
TR201911244T4 (tr) 2019-08-21
CA2981365A1 (en) 2016-10-06
SI3560924T1 (sl) 2021-08-31
US11608338B2 (en) 2023-03-21
IL282584A (en) 2021-06-30
HUE045477T2 (hu) 2019-12-30
PL3277681T3 (pl) 2019-10-31
US20200325137A1 (en) 2020-10-15
CN107889488B (zh) 2020-08-11
WO2016155884A1 (de) 2016-10-06
HRP20191396T1 (hr) 2019-11-01
SG10202002181UA (en) 2020-05-28
EP3868761A1 (de) 2021-08-25
US10975075B2 (en) 2021-04-13
IL254714A0 (en) 2017-11-30
US20190211013A1 (en) 2019-07-11
JP6791873B2 (ja) 2020-11-25
RU2743343C2 (ru) 2021-02-17
EP3560924A1 (de) 2019-10-30
US20230203034A1 (en) 2023-06-29
RS62082B1 (sr) 2021-08-31
EP3868761B1 (de) 2023-03-01
BR112017020941A2 (pt) 2018-07-10
AU2022256215A1 (en) 2022-11-24
US20210198257A1 (en) 2021-07-01
AU2020204241A1 (en) 2020-07-16
US10457677B2 (en) 2019-10-29

Similar Documents

Publication Publication Date Title
MX2017012613A (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
MX2022002581A (es) Compuestos de benzimidazol como inhibidores de c-kit.
MX2023005804A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
PH12018500792A1 (en) Benzolactam compounds as protein kinase inhibitors
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
MX2022002579A (es) Compuestos de aminotiazol como inhibidores de c- kit.
MX2016010571A (es) Pirazolil-ureas como inhibidores de quinasas.
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX2015013481A (es) Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
MD4650B1 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MY173126A (en) Arylquinazolines
PH12017500293A1 (en) Boronic acid derivatives
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
MX2018008362A (es) Derivados de quinolin-2-ona.
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX2017004043A (es) Derivados de acido boronico.
MX2017004037A (es) Derivados de acido boronico.
MX370336B (es) Derivados de acido boronico.
MA39824A (fr) Composés azole amido-substitués
MX2016007810A (es) Derivados de n1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piper idina como inhibidores de piruvato deshidrogenasa cinasa.
MX2019014845A (es) Compuestos de aminotiazol como inhibidores de la proteina quinasa.

Legal Events

Date Code Title Description
FG Grant or registration